Shockwave Medical Gets 10% Jolt, Leads Medical Gear Makers Higher

Upgrade Now

This premium article is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

Should you invest $1,000 in Shockwave Medical right now?

Before you consider Shockwave Medical, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Shockwave Medical wasn't on the list.

While Shockwave Medical currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Companies Mentioned in This Article

Company	MarketRank™	Current Price	Price Change	Dividend Yield	P/E Ratio	Consensus Rating	Consensus Price Target
Shockwave Medical (SWAV)	3.2435 of 5 stars	$175.09	+1.5%	N/A	27.27	Moderate Buy	$263.00
GE HealthCare Technologies (GEHC)	2.5289 of 5 stars	$67.39	-1.0%	0.18%	20.06	Moderate Buy	$84.55
Intuitive Surgical (ISRG)	2.7551 of 5 stars	$311.56	+0.4%	N/A	73.31	Moderate Buy	$344.14
Align Technology (ALGN)	3.2675 of 5 stars	$216.61	-0.1%	N/A	45.89	Moderate Buy	$336.60
Zimmer Biomet (ZBH)	2.5876 of 5 stars	$117.29	+1.0%	0.82%	51.90	Hold	$140.10

Compare These Stocks Add These Stocks to My Watchlist

About Kate Stalter

stalterkate@gmail.com

Contributing Author

Retirement, Asset Allocation, and Tax Strategies

Experience

Kate has been a contributing writer for MarketBeat since 2021.

Areas of Expertise

Asset allocation, technical and fundamental analysis, retirement strategies, income generation, risk management, sector and industry analysis

Education

B.A., Saint Mary’s College, Notre Dame, Indiana; MBA, Kellogg School of Management, Northwestern University

Additional Experience

Series 65-licensed investment advisor, financial advisor, Blue Marlin Advisors; investment columnist for Forbes, U.S. News & World Report

Past Experience

Founder, financial advisor for Better Money Decisions; editor, stock trading instructor for Investor’s Business Daily; columnist, podcast host, video host for MoneyShow.com; contributor for Morningstar magazine

Value Deepens for Medtech Stocks

Results from Johnson & Johnson and Abbott Laboratories foreshadow good news for MedTech investors.Both companies outperformed on the top and bottom lines.